Andrea de Castro

Jan 16, 2024 | biorxiv.org | Christopher Moore |Sareena Rana |Andrea de Castro |Panayiotis Anastasiou

AbstractMutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been approved for use in lung cancer, but responses are short-lived due to rapid development of resistance. In this study we use a novel covalent tri-complex inhibitor, RMC-4998, that targets RASG12C in its active, GTP-bound form to investigate treatment of KRAS mutant lung cancer in various immune competent mouse models.